TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03249402
Drug: JNJ-42847922
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
Study: NCT03862651
Drug: Cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
Study: NCT00654329
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline, given intranasally
Study: NCT00654329
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine, transmucosal, 1 microgram/kilogram
Study: NCT00654329
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine, 2 microgram/kilogram, transmucosal route
Study: NCT01426906
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
Study: NCT01426906
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
Study: NCT04059913
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Study: NCT00814632
Drug: CC-10004
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-10004 20 mg. twice a day for 12 weeks
Study: NCT01319864
Drug: Plerixafor Dose Escalation
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy.
Study: NCT02004132
Drug: Axiron
Normalized name: Axiron
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution administered topically using pump and applicator
Study: NCT04488978
Drug: Irbesartan/Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QID
Study: NCT01319825
Drug: milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
Study: NCT00392704
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy
Study: NCT00392704
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy
Study: NCT00392704
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy
Study: NCT00392704
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
Study: NCT00531063
Drug: Everolimus (RAD001)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00508859
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintenance treatment with sertraline
Study: NCT02459236
Drug: CERC-301
Normalized name: CERC-301
DrugBank: CERC-301 (DB12063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
Study: NCT03749148
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-IL4-Receptor alpha
Study: NCT00046683
Drug: alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004097
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004097
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01878136
Drug: Tissue Plasminogen Activator
Normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
Study: NCT00349245
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04514796
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SB5 (adalimumab), 40 mg, single-dose
Study: NCT00001160
Drug: 68-Gallium Dotatate
Normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For evaluation risk/benefit evaluation
Study: NCT02136342
Drug: chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00873561
Drug: NBI-6024
Normalized name: NBI-6024
DrugBank: NBI-6024 (DB05819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
Study: NCT01273168
Drug: Z-Endoxifen
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
Study: NCT01631617
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800/160 orally every 12 hours for 14 days
Study: NCT01631617
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg orally every 8 hours for 14 days
Study: NCT04111705
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg once daily
Study: NCT04235270
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 10 mg tablet will be administered orally as free combination.
Study: NCT04235270
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 40 mg tablet will be administered orally as free combination.
Study: NCT02489318
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
Study: NCT01474798
Drug: RA-18C3
Normalized name: RA-18C3
DrugBank: Bermekimab (DB14947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection.
Study: NCT03953898
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04640623
Drug: TAR-200
Normalized name: coal tar 200 MG/ML
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAR-200 will be administered transuretherally.
Study: NCT00982540
Drug: caspofungin as preemptive antifungal therapy
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg day 1 followed by 50 mg/day IV
Study: NCT02303847
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
Study: NCT01145417
Drug: pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg-600 mg/day (twice daily)
Study: NCT02435381
Drug: Carisbamate
Normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg Orally on days 2-4
Study: NCT04500808
Drug: Macitentan Dose 1
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Dose 1 of macitentan tablet in Part 1.
Study: NCT04500808
Drug: Macitentan Dose 2
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Dose 2 of macitentan tablet in Part 1.
Study: NCT04500808
Drug: Macitentan Dose 3
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
Study: NCT02176018
Drug: Dextromethorphan and quinidine
Normalized name: dextromethorphan / quinidine
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00666835
Drug: HX575 epoetin alfa Hexal AG
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
Study: NCT01751451
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
Study: NCT01751451
Drug: Abiraterone acetate plus degarelix
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
Study: NCT01751451
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
Study: NCT01659177
Drug: LY2140023
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04127019
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel chemotherapy (injection)
Study: NCT04127019
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy (injection)
Study: NCT04127019
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin chemotherapy (injection)
Study: NCT04127019
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil chemotherapy (injection)
Study: NCT03086070
Drug: Omeprazole 20mg
Normalized name: OMEPRAZOLE 20MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
Study: NCT03689153
Drug: JNJ-63733657
Normalized name: Immunoglobulin G1, anti-(human phosphorylated tau protein) (human-Mus musculus monoclonal JNJ-63733657 γ1-chain), disulfide with human-Mus musculus monoclonal JNJ-63733657 κ-chain, dimer
DrugBank: Posdinemab (DB18941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
Study: NCT01552668
Drug: Fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive 200 mg of fidaxomicin twice daily
Study: NCT00003402
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003402
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02862431
Drug: JNJ-64565111
Normalized name: JNJ-64565111
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT00003402
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003402
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003402
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003402
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03138616
Drug: vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: take 1600 units of vitamin D daily for nine months
Study: NCT04244708
Drug: Radiotherapy plus temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
Study: NCT00412828
Drug: CR011-vcMMAE
Normalized name: cAC10-vcMMAE
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered as an intravenous infusion of 250 mL over 90 min
Study: NCT02519452
Drug: Daratumumab Subcutaneous (SC) Administration
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Study: NCT02276872
Drug: oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04175808
Drug: Omecamtiv Mecarbil (OM)
Normalized name: Sudafed OM
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT04175808
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg moxifloxacin oral tablet
Study: NCT01939483
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00291642
Drug: Placebo tablets matching to levocetirizine
Normalized name: levocetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use
Study: NCT01661244
Drug: RV568 repeat dose
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of escalating repeat doses in normal human volunteers.
Study: NCT02932410
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dispersible tablet; Oral use
Study: NCT03759028
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study: NCT02997228
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02997228
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02581189
Drug: Ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Co-formulated tablet
Study: NCT02581189
Drug: Dasabuvir
Normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT02581189
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT03440788
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
Study: NCT01444547
Drug: paclitaxel and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles.
Study: NCT00291642
Drug: Placebo tablets matching to cetirizine
Normalized name: placebo Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use
Study: NCT02194777
Drug: BIBN 4096 BS - in single rising doses
Normalized name: Rise Prot-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004740
Drug: isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00082706
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
Study: NCT02842125
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral metronomic chemotherapeutic agent
Study: NCT02842125
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Study: NCT02842125
Drug: Opdivo
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Study: NCT01137552
Drug: AMG 780
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 780 will be administered by IV infusion every 2 weeks
Study: NCT02810483
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days.
Study: NCT04531371
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: post surgical agitation prophylaxis
Study: NCT00082706
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days